Introduction {#Sec1}
============

Hepatocellular cancer (HCC) is the most frequent of the primary malignancies of the liver, ranked second and sixth on the list of the most common causes of tumor-related mortality worldwide in men and women, respectively \[[@CR1]\]. Considering the unfavorable prognoses of untreated patients and only moderate response to chemotherapy \[[@CR2], [@CR3]\], surgical treatment is of the utmost importance. Unfortunately, given that the majority of these tumors occur in cirrhotic livers, the use of liver resection is often limited by the presence of portal hypertension and poor hepatic function, as reflected by the guidelines of the Barcelona Clinic Liver Cancer Group \[[@CR4]\]. In contrast, liver transplantation (LT) not only removes all macroscopic and microscopic hepatic tumors with almost no risk of positive oncologic margins, it cures the underlying cirrhosis.

Early experiences with LT for HCC were characterized by an unacceptably high risk of posttransplant tumor recurrence and its related high mortality rate \[[@CR5]\]. This situation was due to a lack of specific selection criteria and performing LT often in patients with large and multifocal tumors. A new era began with adoption of the Milan criteria into clinical practice (single tumor ≤5 cm or two or three tumors ≤3 cm, with no evidence of extrahepatic metastases or macrovascular invasion) \[[@CR6]\]. Based on the results of several observational studies, expansions of these restrictive criteria have been proposed. One criteria set is that of the University of California, San Francisco (UCSF) with criteria of a single tumor \<6.5 cm or two or three tumors \<4.5 cm, total tumor diameter \<8 cm. Another criteria set is the Up-to-7 criteria (size of the largest tumor + number of tumors ≤7) \[[@CR7], [@CR8]\]. Even though the conservative Milan criteria are still widely used for selecting patients with HCC to undergo LT, outcomes after LT for HCC remain inferior to those performed for benign indications \[[@CR9], [@CR10]\]. Because the inferior outcomes of HCC patients are mainly due to posttransplant tumor recurrence, the use of expansions of the Milan criteria that are already based solely on morphologic tumor characteristics would not eliminate these discrepancies. During this era of severe shortage of available organs and increasing demand for LT, there is general agreement in the transplant community that posttransplant outcomes of HCC patients should be similar to those undergoing transplantation for other indications \[[@CR11]\]. Optimization of the existing selection criteria seems crucial to achieve this goal.

Historically, the serum α-fetoprotein (AFP) concentration was applied for HCC screening among high-risk groups and to establish the diagnosis. Considering its poor diagnostic features, it is no longer recommended in these clinical settings \[[@CR12], [@CR13]\]. Nevertheless, AFP is currently gaining an increasing role as a marker of biologic aggressiveness of tumors. Numerous studies confirmed the prognostic significance of preoperative AFP in both liver resection and LT \[[@CR14]--[@CR18]\]. However, there is no agreement as to the most appropriate cutoff for AFP when selecting HCC patients for LT \[[@CR11]\]. The purpose of this study was to evaluate the exact role of AFP in selecting HCC patients at minimal risk of posttransplant tumor recurrence in the setting of the existing criteria.

Material and methods {#Sec2}
====================

A total of 1,115 LTs were performed in the Department of General, Transplant, and Liver Surgery at the Medical University of Warsaw between December 1994 and June 2012. Basing on the results of explant pathology, 121 HCC patients were included in this retrospective cohort study. Patients with combined hepatocellular/cholangiocellular cancer (*n* = 3), fibrolamellar HCC (*n* = 3), sarcomatous HCC (*n* = 1), or macroscopic vascular invasion (*n* = 6) were excluded. The ethics committee of the Medical University of Warsaw approved the study protocol. Details on the operative technique, postoperative immunosuppression, and follow-up visits were described previously \[[@CR15], [@CR19]\].

The last available pretransplant AFP was collected (usually measured within 24 h preceding transplantation). Tumor recurrences at 3 and 5 years were set as primary and secondary end points of the study, respectively. They were used to calculate the corresponding recurrence-free survival rates (observations were censored at the time of the last follow-up or death caused by conditions other than tumor recurrence). In general, risk factors for HCC recurrence at 3 years were established in univariate analyses. Subsequently, the associations between AFP and hazard of recurrence were adjusted for the impact of potential confounders in a series of bivariate analyses. Establishment of the optimal cutoffs for AFP for predicting HCC recurrence at 3 years was based on true-positive (TP) and false-positive (FP) prediction rates derived from estimated 3-year recurrence-free survival rates of patients with AFP levels higher and lower than the following values: 10, 20, 35, 50, and 100--1000 ng/ml (at 100 ng/ml intervals). TP and FP rates were calculated using the following equations:$$\documentclass[12pt]{minimal}
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To the best of our knowledge, this novel methodologic approach allowed estimation of the optimal AFP cutoff values for predicting the 3-year recurrence rate even though the observation period was less than 3 years for some patients. For this reason, receiver operating characteristics curves were not used. Notably, the evaluation of the risk factors for HCC recurrence and AFP cutoffs was based on the first three posttransplant years when the vast majority of recurrent tumors are diagnosed \[[@CR20]\]. Nevertheless, recurrence-free survivals of patients whose AFP levels were below and above the estimated AFP cutoffs were validated also within a time frame of five posttransplant years.

Data are presented as the median (range) for continuous variables and the number (%) for categoric variables. Associations between AFP and categoric and continuous variables were assessed with the Mann--Whitney *U* test and Spearman's correlation coefficient, respectively. Survival estimates were based on the Kaplan--Meier method. Survival curves were compared using a log-rank test. Cox's proportional hazards regression was used to evaluate risk factors for HCC recurrence in univariate and bivariate analyses. Linearity of the associations between AFP and recurrence hazard was assessed in general additive models and presented as spline functions. Hazard ratios (HRs) were presented with 95 % confidence intervals (95 % CI). The level of statistical significance was set at 0.05. All analyses were computed in SAS version 9.3 (SAS Institute, Cary, NC, USA) and S-Plus version 6.1 (TIBCO Software, Palo Alto, CA, USA).

Results {#Sec3}
=======

Baseline characteristics of the 121 patients included in the study cohort are shown in Table [1](#Tab1){ref-type="table"}. Median follow-up for the entire study cohort was 30 months. There was a positive correlation between AFP and the size of the largest tumor that verged on significance (*p* = 0.050) (Table [2](#Tab2){ref-type="table"}). Significantly higher AFP was also noted in patients of female sex (*p* = 0.009), with hepatitis C virus-related cirrhosis (*p* = 0.010), without hepatitis B virus infection (*p* = 0.032), or with nonincidental tumors (*p* = 0.024) (Table [3](#Tab3){ref-type="table"}). Although the associations between AFP and microvascular invasion (*p* = 0.252) or tumor differentiation (*p* = 0.775) did not reach the level of significance, the median AFP level was markedly higher for patients with microvascular invasion or poorly differentiated tumors.Table 1Characteristics of 121 patients included in the study cohortFactorMedian (range) or no. (%)General factors Recipient age (years)55 (20--67) Recipient sex  Female29 (24.0 %)  Male92 (76.0 %) Child-Turcotte-Pugh class  A54 (44.6 %)  B50 (41.3 %)  C17 (14.1 %) Model for end-stage liver disease (points)11 (6--40) Hepatitis C virus infection77 (63.6 %) Hepatitis B virus infection45 (37.2 %) Alcoholic cirrhosis26 (21.5 %) Donor age (years)48 (16--70) Donor sex  Female33 (27.3 %)  Male88 (72.7 %) Cold ischemia (hours)7.9 (2.9--11.8)Fulfillment of selection criteria Milan67 (55.4 %) UCSF83 (68.6 %) Up-to-790 (74.4 %) Tumor-related factors Serum AFP concentration (ng/ml)23.7 (1.4--36208.0) Size of largest tumor (cm)^a^3.4 (0.3--14.0) No. of tumors^a^2 (1--10) Total tumor volume (cm^3^)^a,b^22.5 (0.02--5277.9) Microvascular invasion^a^37 (31.6 %) Poor tumor differentiation^a^13 (10.7 %) Bilateral tumors^a^33 (27.3 %) Neodjuvant therapy42 (34.7 %)  Chemoembolization22 (18.2 %)  Ablation13 (10.7 %)  Both7 (5.8 %) Salvage liver transplantation9 (7.4 %) Incidental tumors13 (10.7 %)Intraoperative factors Surgical technique  Piggyback101 (83.5 %)  Conventional20 (16.5 %) Packed RBC transfusions (units)4 (0--48) FFP transfusions (units)8 (0--50) Total operative time (hours)7.0 (3.8--12.0) Duration of hepatectomy (hours)3.0 (1.5--5.1) Warm ischemia (minutes)68.5 (25.0--195.0)*UCSF* University of California, San Francisco, *AFP* α-fetoprotein, *RBC* red blood cell, *FFP* fresh frozen plasma^a^Based on explant pathology^b^Calculated as a sum of estimated volumes of each tumor (4/3πr^3^)Table 2Associations between serum AFP concentration and other continuous variablesVariable 1Variable 2Correlation coefficient*p*AFPRecipient age0.0460.627AFPModel for end-stage liver disease score--0.0370.691AFPSize of the largest tumor0.1850.050AFPNo. of tumors0.0220.816AFPTotal tumor volume0.1590.100Table 3Associations between serum AFP concentration and categoric variablesVariableAFP (ng/ml)MedianRange*p*Recipient sex0.009 Female124.33.3--17500.0 Male15.51.4--36208.0Child-Turcotte-Pugh class0.173 A30.71.6--36208.0 B34.52.0--7053.0 C9.21.4--17500.0Hepatitis C virus infection0.010 No10.61.9--7053.0 Yes43.11.4--36208.0Hepatitis B virus infection0.032 No41.81.4--36208.0 Yes10.21.9--23231.0Alcoholic cirrhosis0.358 No28.21.6--36208.0 Yes16.01.4--7053.0Milan criteria0.196 Within18.81.6--813.3 Beyond39.51.4--36208.0UCSF criteria0.648 Within25.21.6--23231.0 Beyond21.41.4--36208.0Up-to-7 criteria0.500 Within24.71.6--23231.0 Beyond21.61.4--36208.0Microvascular invasion0.252 No15.51.6--23231.0 Yes39.51.4--36208.0Tumor differentiation0.775 Well41.82.6--7053.0 Moderate22.41.4--36208.0 Poor93.62.9--23231.0Bilateral tumors0.698 No18.81.6--36208.0 Yes38.01.4--17500.0Neoadjuvant therapy0.652 No21.11.4--23231.0 Yes31.61.6--36208.0Salvage liver transplantation0.293 No20.61.4--23231.0 Yes141.01.9--36208.0Incidental tumors0.024 No27.91.4--36208.0 Yes8.33.3--69.2

AFP was a significant risk factor for tumor recurrence (*p* \< 0.001) in the univariate analyses (Table [4](#Tab4){ref-type="table"}). Among the remaining factors, the hazard of recurrence was significantly influenced by the size of the largest tumor (*p* \< 0.001), number of tumors (*p* = 0.017), total tumor volume (*p* = 0.001), tumors beyond the Milan criteria (*p* = 0.022) or the Up-to-7 criteria (*p* = 0.021), recipient age (*p* = 0.044), donor sex (*p* = 0.009), and conventional LT technique (*p* = 0.004). Controlled for each of the potential confounders considered in this study, AFP retained significance as a risk factor for posttransplant HCC recurrence in all of the bivariate models (Table [5](#Tab5){ref-type="table"}). Tumors of higher diameter (*p* = 0.010), those beyond the Milan criteria (*p* = 0.044), and female sex of the donor (*p* = 0.029) increased the risk of HCC recurrence independently of the pretransplant AFP level. All associations between AFP and posttransplant recurrence risk were nearly linear in the univariate analyses (linear effect *p* \< 0.001; nonlinear effect *p* = 0.434) and bivariate analyses (linear effects: *p* \< 0.001--0.034; nonlinear effects *p* *=* 0.120--0.730) (Fig. [1](#Fig1){ref-type="fig"}).Table 4Univariates analyses of risk factors for recurrence during the first three posttransplant yearsFactorsHR95 % CI*p*Serum AFP concentration1.40^a^1.20--1.63\<0.001Size of the largest tumor1.48^b^1.20--1.83\<0.001No. of tumors1.21^c^1.03--1.410.017Total tumor volume1.03^d^1.01--1.050.001Microvascular invasion1.950.63--6.040.248Poor tumor differentiation2.630.54--12.710.230Bilateral tumors0.700.19--2.540.586Neoadjuvant therapy1.500.49--4.620.479Salvage liver transplantation2.690.59--12.200.200Incidental tumors0.700.09--5.400.734Tumors beyond Milan criteria4.551.25--16.670.022Tumors beyond UCSF criteria2.540.85--7.580.095Tumors beyond Up-to-7 criteria3.641.22--10.870.021Recipient age0.62^e^0.39--0.990.044Recipient sex0.76^f^0.23--2.450.641Child-Turcotte-Pugh class C1.100.21--5.670.913Model for end-stage liver disease1.03^g^0.94--1.120.561Hepatitis C virus infection0.950.31--2.910.931Hepatitis B virus infection1.390.47--4.140.555Alcoholic cirrhosis1.010.22--4.560.996Donor age0.76^e^0.50--1.160.202Donor sex0.23^f^0.08--0.690.009Cold ischemia1.45^h^0.84--2.520.187Conventional technique for liver transplantation4.991.68--14.870.004Packed RBC transfusions0.95^i^0.78--1.150.569FFP transfusions0.86^i^0.66--1.110.236Total operative time1.16^h^0.75--1.800.503Duration of hepatectomy0.63^h^0.247--1.620.340Warm ischemia1.05^j^0.85--1.290.662*HR* hazard ratio, *CI* confidence interval^a^increase by 100 ng/ml^b^Increase by 1 cm^c^Increase by 1 tumor^d^Increase by 10 cm^3e^Increase by 10 years^f^Male sex^g^Increase by 1 point^h^Increase by 1 h^i^Increase by 1 unit^j^Increase by 10 minTable 5Association between AFP and the risk of tumor recurrence 3 years after exclusion of the impact of potential confounders in a series of bivariate modelsFactor 1HR (95 % CI)^a^*p*Factor 2HR (95 % CI)*p*AFP1.21 (1.02--1.45)0.032Size of largest tumor1.41 (1.09--1.82)^*b*^0.010AFP1.34 (1.13--1.59)\<0.001No. of tumors1.10 (0.92--1.31)^*c*^0.314AFP1.46 (1.17--1.82)\<0.001Total tumor volume1.02 (0.99--1.04)^d^0.112AFP1.43 (1.20--1.71)\<0.001Microvascular invasion1.86 (0.51--6.82)0.348AFP1.43 (1.22--1.69)\<0.001Poor tumor differentiation1.92 (0.39--9.44)0.421AFP1.42 (1.21--1.66)\<0.001Bilateral tumors0.62 (0.16--2.44)0.489AFP1.40 (1.20--1.63)\<0.001Neoadjuvant therapy1.49 (0.44--5.01)0.524AFP1.40 (1.20--1.63)\<0.001Salvage LT1.56 (0.19--12.78)0.681AFP1.38 (1.19-1.61)\<0.001Incidental tumors---0.995AFP1.31 (1.14--1.52)\<0.001Milan criteria8.62 (1.06--71.43)^e^0.044AFP1.36 (1.16--1.58)\<0.001UCSF criteria2.34 (0.65--8.47)^e^0.196AFP1.33 (1.14--1.54)\<0.001Up-to-7 criteria3.30 (0.89-12.20)^e^0.074AFP1.39 (1.19--1.62)\<0.001Recipient age0.82 (0.43-1.57)^f^0.555AFP1.49 (1.26--1.76)\<0.001Recipient sex (male)3.10 (0.70-13.81)0.137AFP1.47 (1.24--1.75)\<0.001Child-Turcotte-Pugh class1.03 (0.31-3.41)^g^0.967AFP1.39 (1.19--1.62)\<0.001Model for end-stage liver disease1.03 (0.91-1.16)^h^0.647AFP1.40 (1.21--1.63)\<0.001Hepatitis C virus infection0.84 (0.24--2.90)0.781AFP1.40 (1.20--1.64)\<0.001Hepatitis B virus infection1.01 (0.29--3.47)0.986AFP1.40 (1.20--1.63)\<0.001Alcoholic liver disease1.35 (0.28--6.44)0.710AFP1.38 (1.16--1.65)\<0.001Donor age1.07 (0.66--1.74)^f^0.791AFP1.36 (1.16--1.59)\<0.001Donor sex (male)0.24 (0.07--0.86)0.029AFP1.31 (1.08--1.60)0.008Cold ischemia1.43 (0.81--2.54)^i^0.221AFP1.34 (1.14--1.57)\<0.001Conventional LT technique2.52 (0.68--9.34)0.166AFP1.33 (1.12--1.58)0.001Packed RBC transfusions0.93 (0.74--1.16)^j^0.501AFP1.37 (1.14--1.64)\<0.001FFP transfusions0.84 (0.66--1.06)^j^0.141AFP1.33 (1.10--1.60)0.003Total operative time0.97 (0.63--1.48)^i^0.883AFP1.37 (1.10--1.70)0.005Duration of hepatectomy0.55 (0.21--1.44)^i^0.226AFP1.40 (1.14--1.72)0.001Warm ischemia0.96 (0.79--1.17)^k^0.696Each row represents results of separate bivariate analysis*HR* hazard ratio, *LT* liver transplantation^a^Increase by 100 ng/ml^b^Increase by 1 cm^c^Increase by 1 tumor^d^Increase by 10 cm^3e^Tumors beyond^f^Increase by 10 years^g^Class C^h^Increase by one point^i^Increase by 1 h^j^Increase by 1 unit^k^Increase by 10 minFig. 1Associations between serum α-fetoprotein (AFP) concentration and the risk of posttransplant tumor recurrence in the univariate analysis (**a**) and adjusted for the impact of potential confounders, including general factors (**b**), tumor-related factors (**c**), intraoperative factors (**d**), and fulfillment of selection criteria (**e**). Risk curves (*solid lines*) are presented with 95 % confidence intervals (*dotted line*s)

More precisely, AFP predicted HCC recurrence in patients beyond (*p* \< 0.001) the Milan criteria, within (*p* = 0.001) or beyond (*p* = 0.015) the UCSF criteria, or within (*p* = 0.001) or beyond (*p* = 0.023) the Up-to-7 criteria---but not in patients within (*p* = 0.834) the Milan criteria (Table [6](#Tab6){ref-type="table"}). Thus, AFP cutoffs were estimated for all of these groups except for the latter. Accordingly, the AFP cutoff was 100 ng/ml for patients within the UCSF criteria (TP = 100 %, FP = 24.2 %). The cutoff was the same for patients within (TP = 100 %, FP = 24.7 %) or beyond (TP = 63.4 %, FP = 15.6 %) the Up-to-7 criteria. However, it was 200 ng/ml for patients beyond the Milan criteria (TP = 70.5 %, FP = 9.8 %) and the UCSF criteria (TP = 58.1 %, FP = 12.5 %) (Fig. [2](#Fig2){ref-type="fig"}).Table 6Associations between serum AFP concentration and risk of posttransplant tumor recurrence at 3 years in patients within and beyond the Milan, University of California, San Francisco, and Up-to-7 criteriaCriteriaFactorHR (95% CI)^a^*p*Milan WithinAFP1.09 (0.47--2.53)0.834 BeyondAFP1.32 (1.14--1.53)\<0.001UCSF WithinAFP1.64 (1.21--2.21)0.001 BeyondAFP1.24 (1.04--1.47)0.015Up-to-7 WithinAFP1.66 (1.22--2.25)0.001 BeyondAFP1.21 (1.03--1.43)0.023^a^Per 100 ng/ml increaseFig. 2Estimation of the optimal cutoffs for serum AFP concentration for predicting posttransplant tumor recurrence in patients within the University of California, San Francisco (UCSF) (**a**) and Up-to-7 (**b**) criteria and beyond the Milan (**c**), UCSF (**d**), and Up-to-7 (**e)** criteria

Recurrence-free survivals at 1, 3, and 5 years after LT were 93.9, 83.6, and 76.8 %, respectively, for the entire study cohort. There was no difference with respect to the 5-year recurrence-free survival between patients within the Milan criteria and those beyond them but with AFP \>200 ng/ml (88.8 vs. 75.5 %; *p* = 0.201) (Fig. [3](#Fig3){ref-type="fig"}a). Patients within the UCSF criteria and AFP \<100 ng/ml exhibited superior recurrence-free survival at 5 years (100 %) compared to patients within these criteria but with AFP \>100 ng/ml) (69.0 %) or beyond these criteria and AFP \<200 ng/ml (64.3 %; *p* = 0.005) (Fig. [3](#Fig3){ref-type="fig"}b). Similarly, the 5-year recurrence-free survival of patients within the Up-to-7 criteria and AFP \<100 ng/ml (100 %) was superior to the corresponding rates in patients within and beyond these criteria and AFP \>100 ng/ml (71.9 %) or \<100 ng/ml (47.8 %), respectively (*p* = 0.001) (Fig. [3](#Fig3){ref-type="fig"}c).Fig. 3Recurrence-free survivals. **a** Patients within the Milan criteria (*dashed line*) and beyond the Milan criteria (*solid line*) with AFP \<200 ng/ml. **b** Patients within UCSF criteria with AFP \<100 ng/ml (*dashed line*) and \>100 ng/ml (*dashed-dotted line*) and beyond the UCSF criteria with AFP \<200 ng/ml (*solid line*). **c** Patients within Up-to-7 criteria with AFP \<100 ng/ml (*dashed line*) and \>100 ng/ml (*dashed-dotted line*) and beyond Up-to-7 criteria (*solid line*) with AFP \<100 ng/ml. Survival curves are presented with 95 % confidence intervals

Discussion {#Sec4}
==========

The Milan criteria are consistently being criticized for being too restrictive \[[@CR7], [@CR8], [@CR21], [@CR22]\]. In fact, it has been shown in several studies that the use of expanded criteria, such as the UCSF or Up-to-7 proposals, might provide results comparable to those provided by the use of Milan criteria \[[@CR7], [@CR8], [@CR23], [@CR24]\]. At the same time, large-scale national-level studies indicate that HCC is associated with inferior posttransplant outcomes compared to other indications \[[@CR9], [@CR10]\]. In fact, the "Metroticket" concept of the authors of Up-to-7 criteria illustrates that expansion of the limits for morphologic tumor features during selection to undergo LT would further alter the posttransplant outcomes \[[@CR8]\]. Moreover, the number of LTs performed for HCC has rapidly increased over the last several years \[[@CR10]\]. With the limited pool of deceased donors, this situation might be harmful to patients with other indications for LT because it prolongs their waiting time, resulting in increased deaths while still on the waiting list. Under these circumstances, the HCC Consensus Group stated that the outcomes after LT for HCC and other indications should be comparable \[[@CR11]\]. Thus, the optimal selection criteria should ideally bring the risk of posttransplant tumor recurrence to zero.

The results of this study that support the rationale for including AFP in the existing criteria are in line with the findings in previous reports. Notably, both AFP and the size of the largest tumor were independent predictors of tumor recurrence, whereas the number of tumors did not reach the level of significance after adjusting for the impact of the AFP level. However, as the nature of this study was retrospective, such observation clearly does not preclude the importance of the number of tumors during the qualification of patients with HCC for transplantation due to the potential of selection bias. Accordingly, the existing and already popular selection criteria were used to determine the optimal AFP cutoffs subsequently used to develop a strategy for their modification. Analysis of the spline curves revealed linearity of the associations between AFP and the risk of HCC recurrence. Hence, these cutoffs were based on prediction curves derived from Kaplan-Meier recurrence-free survival estimates.

The major finding of the present study is that the estimated rate of tumor recurrence at 5 years was 0 % (corresponding to recurrence-free survival of 100 %) in patients with AFP levels \<100 ng/ml and with a tumor burden within the limits of either the UCSF or Up-to-7 criteria. These results support selection of HCC patients with such characteristics for LT either as an addition to the Milan criteria or even their replacement. In both cases, prospective validation of the UCSF or Up-to-7 criteria modified with the 100 ng/ml AFP cutoff in an unselected cohort of HCC patients would be necessary to confirm the rationale for their clinical use. Nevertheless, the proposal for slight expansion of the Milan criteria only to patients with minimal risk of HCC tumor recurrence seems to be a reasonable alternative to expanding the selection criteria to include patients with moderate risk that is comparable to or slightly higher than that provided by the Milan criteria.

Interestingly, recurrence-free survival of patients within the UCSF criteria and AFP levels over the estimated cutoff was similar to those beyond them but with AFP levels \<200 ng/ml. In contrast, patients beyond the Up-to-7 criteria and AFP \<100 ng/ml exhibited a markedly higher recurrence rate than patients within the Up-to-7 criteria but with AFP \>100 ng/ml. Most importantly, tumor recurrences were observed in a remarkable proportion of patients from each of these subgroups. Considering the principle of minimizing the risk of tumor recurrence to achieve outcomes comparable to those seen with other indications, selection of these patients for LT is highly controversial.

Several selection criteria utilizing AFP have been proposed to date, such as the Hangzhou criteria, Seoul criteria, and total tumor volume/AFP (TTV/AFP) criteria. Seoul criteria were defined as the size of the largest tumor ≤5 cm and AFP \<400 ng/ml regardless of the number of tumors \[[@CR25]\]. The authors of the Hangzhou criteria proposed an identical cutoff. They stated that all patients who had well or moderately differentiated tumors and AFP \<400 ng/ml might be considered eligible for LT \[[@CR26]\]. However, according to the present study, a cutoff for AFP of 400 ng/ml would lead to a marked increase in the recurrence rate, even in patients who were within the UCSF or Up-to-7 criteria, which are clearly were more restrictive with respect to morphological features than the Seoul or Hangzhou proposals. Conversely, TTV/AFP criteria (TTV \< 115 cm^3^ + AFP \<400 ng/ml) were associated with superior survival rates in the original study \[[@CR27]\] and very low recurrence rate at 5 years in their recent retrospective validation study at the same institution as the authors of the current study \[[@CR28]\]. However, as both studies were retrospective and the morphologic limits quite liberal, the results might have been subject to selection bias. Moreover, their fulfillment still did not eliminate the problem of HCC recurrence.

Duvoux et al. \[[@CR29]\] also evaluated the concept of combining AFP with morphologic features of the tumor. Based on the AFP levels, tumor size, and number of tumor nodules, the authors of that highly relevant report introduced a predictive model for tumor recurrence that is superior to the Milan criteria for categorizing patients into low- and high-risk groups. In contrast to this interesting proposal of absolute replacement of the Milan criteria with a new risk index, the results of the present study point toward the potential of slight expansion of the former without a negative impact on the risk of recurrence.

In a study based on 92 patients after LT for HCC, Yaprak et al. \[[@CR30]\] found that those at low- and high-risk of tumor recurrence can be distinguished based on their AFP level. However, there are several differences between their study and the present study. First, the cutoffs for AFP utilized by Yaprak et al. were arbitrary and hence identical for patients within and beyond the Milan criteria. Notably, the results of the present study indicate that the optimal cutoffs may substantially differ between patients within and beyond particular selection criteria, which seems natural given the correlation between AFP and tumor size. Moreover, the results obtained in the present study highlight the linear nature of the association between AFP and the risk of recurrence, which may prove useful in clinical practice regardless of whether the suggested expansion of selection criteria is adopted. Finally, the results not only confirm the prognostic role of AFP in LT for HCC. They provide additional data to support the rationale for safe utilization of the expanded criteria when limited by the AFP level.

Finally, some authors have suggested that a pretransplant AFP slope is superior to single absolute values \[[@CR31]\]. According to a study by Dumitra et al. \[[@CR32]\] based on the data of 92 HCC liver transplant recipients, a rising AFP slope was strongly associated with tumor recurrence. However, the positive predictive value of the rising AFP slope was only 25.0 % in that study. On the other hand, results of a large study including 6,817 patients by Merani et al. \[[@CR33]\] indicated that the last preoperative AFP level is what matters the most, as patients with stable high AFP and those with originally low but increasing AFP have similar prognoses.

Notably, the usefulness of AFP as an important risk factor for postoperative outcomes was also previously confirmed for patients with HCCs in a noncirrhotic setting. Specifically, Witjes et al. \[[@CR34]\] analyzed the data from 94 patients with HCC in noncirrhotic livers and found that AFP and the presence of microvascular invasion were the only independent risk factors for tumor recurrence. Although such patients are not currently considered suitable for LT, these results indicate that AFP should also be taken into consideration when establishing selection criteria for LT in future studies.

Among other potential markers for HCC aggressiveness in a liver transplant setting, des-γ-carboxyprothrombin (DCP) is the one most frequently studied. The results of other studies comparing AFP and DCP as predictors of poor outcomes are contradictory. Hence, there is no clear evidence for superiority of one over another \[[@CR35], [@CR36]\]. Unfortunately, pretransplant DCP was not assessed in patients included in the present study.

Conclusion {#Sec5}
==========

Given the minimal risk of posttransplant recurrence, patients who are within Up-to-7 or UCSF criteria should be considered eligible for LT provided the AFP level is \<100 ng/ml.

None.
